Mentioned On
Episode Mentions
Pharma and BioTech Daily · Jul 28, 2026
AstraZeneca's $80B Target Amid Setbacks? | Pharma and Biotech Daily
“Achieved FDA approval for Lidenava (reformulated Roxavastin) for wet AMD after three prior rejections”
Antibody-Drug Conjugates (ADCs) in OncologyNon-Stimulant ADHD TherapeuticsDuchenne Muscular Dystrophy (DMD) Treatments
View Analysis